OBJECTIVES: To evaluate the feasibility and efficacy of a continuous glucose monitoring system (CGMS) in a population of infants of very low birth weight (VLBW). STUDY DESIGN: Infants weighing <or=1,500 g and of <or=32 weeks of gestation were recruited within 24 h of delivery. A subcutaneous sensor connected to a CGMS was inserted and maintained for 7 days or until dysfunction. Therapeutic management followed the usual standard protocols. RESULTS: 38 patients (21 male) were included over 17 months. Their mean gestational age was 27.5 +/- 2.0 weeks and their mean birth weight was 958.3 +/- 205.5 g. Their perinatal histories and complications during admission were unremarkable for extremely premature babies. Continuous monitoring lasted an average of 7.84 +/- 1.99 days per patient. Hyperglycaemia was detected in 22 (57.90%) patients and it lasted a mean of 20.33 +/- 30.13 h, while 14 (36.8%) presented with hypoglycaemia for a mean of 2.45 +/- 2.3 h. CONCLUSIONS: The CGMS gave a safe and useful estimate of glucose levels in VLBW infants, revealing abnormal glucose levels at a much higher rate than expected by usual sampling. However, it was not able to provide real-time glucose concentration data. CGMS may be very useful in providing information on the role of hyper- and hypoglycaemia on short- and long-term outcomes in VLBW infants.
OBJECTIVES: To evaluate the feasibility and efficacy of a continuous glucose monitoring system (CGMS) in a population of infants of very low birth weight (VLBW). STUDY DESIGN:Infants weighing <or=1,500 g and of <or=32 weeks of gestation were recruited within 24 h of delivery. A subcutaneous sensor connected to a CGMS was inserted and maintained for 7 days or until dysfunction. Therapeutic management followed the usual standard protocols. RESULTS: 38 patients (21 male) were included over 17 months. Their mean gestational age was 27.5 +/- 2.0 weeks and their mean birth weight was 958.3 +/- 205.5 g. Their perinatal histories and complications during admission were unremarkable for extremely premature babies. Continuous monitoring lasted an average of 7.84 +/- 1.99 days per patient. Hyperglycaemia was detected in 22 (57.90%) patients and it lasted a mean of 20.33 +/- 30.13 h, while 14 (36.8%) presented with hypoglycaemia for a mean of 2.45 +/- 2.3 h. CONCLUSIONS: The CGMS gave a safe and useful estimate of glucose levels in VLBW infants, revealing abnormal glucose levels at a much higher rate than expected by usual sampling. However, it was not able to provide real-time glucose concentration data. CGMS may be very useful in providing information on the role of hyper- and hypoglycaemia on short- and long-term outcomes in VLBW infants.
Authors: Matthew Signal; Aaron Le Compte; Deborah L Harris; Philip J Weston; Jane E Harding; J Geoffrey Chase Journal: Diabetes Technol Ther Date: 2012-08-02 Impact factor: 6.118
Authors: Petr Kopecký; Miloš Mráz; Jan Bláha; Jaroslav Lindner; Stĕpán Svačina; Roman Hovorka; Martin Haluzík Journal: Biomed Res Int Date: 2013-02-20 Impact factor: 3.411
Authors: N Margreth van der Lugt; Vivianne E H J Smits-Wintjens; Paul H T van Zwieten; Frans J Walther Journal: BMC Pediatr Date: 2010-07-20 Impact factor: 2.125
Authors: Joanne E Hegarty; Jane M Alsweiler; Gregory G Gamble; Caroline A Crowther; Jane E Harding Journal: J Pediatr Date: 2021-03-30 Impact factor: 6.314